Enhabit (EHAB) Stock Overview
Provides home health and hospice services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
EHAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Enhabit, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.75 |
| 52 Week High | US$14.22 |
| 52 Week Low | US$6.47 |
| Beta | 1.08 |
| 1 Month Change | -1.79% |
| 3 Month Change | 27.08% |
| 1 Year Change | 72.52% |
| 3 Year Change | 1.93% |
| 5 Year Change | n/a |
| Change since IPO | -45.00% |
Recent News & Updates
EHAB: Kinderhook Cash Offer And Deal Completion Will Shape Forward Risk Balance
Analysts have aligned Enhabit’s updated fair value estimate with the agreed Kinderhook Industries takeout price, trimming the target by $0.03 to $13.80 as they factor in the all cash $13.80 per share acquisition and modest tweaks to growth, margin and discount rate assumptions. Analyst Commentary Street research has largely converged around Enhabit’s agreed takeout price, with multiple firms resetting ratings and targets to align with the US$13.80 per share all cash offer from Kinderhook Industries.EHAB: Cash Sale Terms And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have inched their average price target for Enhabit up by about $0.03 to roughly $13.83, reflecting recent research that aligns estimates with the agreed all cash acquisition price of $13.80 per share. Analyst Commentary Recent research on Enhabit has shifted quickly after the announced all cash acquisition at $13.80 per share, with most commentary now centered on how closely the stock aligns with the agreed deal value rather than on long term standalone upside.EHAB: Kinderhook Cash Deal And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have adjusted Enhabit’s price target to $13.80 per share, in line with the agreed all cash acquisition price from Kinderhook Industries. They cite the pending takeout and recent shifts in ratings to Hold, Neutral, Perform and Market Perform at multiple firms as the key drivers of this update.EHAB: Kinderhook Cash Takeout And Sector Reimbursement Trends Will Shape Forward Risk Balance
The analyst price target for Enhabit has been adjusted from $13.08 to $13.80. Analysts cite the agreed all-cash acquisition by Kinderhook Industries at $13.80 per share as the primary reference point for the valuation.Recent updates
EHAB: Kinderhook Cash Offer And Deal Completion Will Shape Forward Risk Balance
Analysts have aligned Enhabit’s updated fair value estimate with the agreed Kinderhook Industries takeout price, trimming the target by $0.03 to $13.80 as they factor in the all cash $13.80 per share acquisition and modest tweaks to growth, margin and discount rate assumptions. Analyst Commentary Street research has largely converged around Enhabit’s agreed takeout price, with multiple firms resetting ratings and targets to align with the US$13.80 per share all cash offer from Kinderhook Industries.EHAB: Cash Sale Terms And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have inched their average price target for Enhabit up by about $0.03 to roughly $13.83, reflecting recent research that aligns estimates with the agreed all cash acquisition price of $13.80 per share. Analyst Commentary Recent research on Enhabit has shifted quickly after the announced all cash acquisition at $13.80 per share, with most commentary now centered on how closely the stock aligns with the agreed deal value rather than on long term standalone upside.EHAB: Kinderhook Cash Deal And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have adjusted Enhabit’s price target to $13.80 per share, in line with the agreed all cash acquisition price from Kinderhook Industries. They cite the pending takeout and recent shifts in ratings to Hold, Neutral, Perform and Market Perform at multiple firms as the key drivers of this update.EHAB: Kinderhook Cash Takeout And Sector Reimbursement Trends Will Shape Forward Risk Balance
The analyst price target for Enhabit has been adjusted from $13.08 to $13.80. Analysts cite the agreed all-cash acquisition by Kinderhook Industries at $13.80 per share as the primary reference point for the valuation.Enhabit: Why This Healthcare Buyout Won't Raise FTC Alarms
Feb 25EHAB: Takeout At 13.80 And Reimbursement Clarity Will Shape Forward Risk Balance
The analyst price target for Enhabit has been raised from $11.75 to $13.08. Analysts cited the agreed all-cash acquisition at $13.80 per share and related updates to assumed future P/E as the key drivers of the change.EHAB: Clearer Reimbursement And Mixed Ratings Will Shape Forward Risk Balance
Narrative Update on Enhabit The analyst price target for Enhabit has moved to $11.75. Analysts note that clearer home health reimbursement rules, an improved regulatory backdrop, and what they describe as a discounted valuation support a more constructive stance on the shares.EHAB: Clearer Reimbursement And Mixed Ratings Will Shape Future Earnings Visibility
Narrative Update The analyst price target for Enhabit has shifted from $10.60 to $11.75, as analysts factor in an improved home health reimbursement backdrop, clearer earnings visibility, and reduced regulatory overhang reflected in recent upgrades and higher targets around $12. Analyst Commentary Recent research on Enhabit has turned more positive, with several firms lifting ratings and price targets to around US$12 as the regulatory picture for home health reimbursement becomes clearer.EHAB: Final Rule Clarity And Mixed Ratings Will Shape Earnings Outlook
Analysts have lifted their price expectations for Enhabit, with our fair value estimate moving from US$9.38 to US$10.60. They point to greater earnings clarity following the final home health rule, a modest adjustment to discount rates and profit assumptions, and recent research that highlights both improving operations and what some see as a discounted valuation.Aging Demographics Will Fuel US Home Care Expansion
Despite a notable improvement in net profit margin and a lower future P/E ratio, the consensus analyst price target for Enhabit has been reduced from $10.00 to $9.38. What's in the News Enhabit, Inc.Enhabit, Inc. (NYSE:EHAB) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Jul 03
Enhabit (NYSE:EHAB) Has A Pretty Healthy Balance Sheet
Jun 14US Home Health Demand And Value-Based Care Will Create Future Opportunities
Structural trends and targeted expansion in underserved markets are driving sustained revenue growth and building a reliable recurring revenue base.Returns On Capital At Enhabit (NYSE:EHAB) Paint A Concerning Picture
May 09Enhabit, Inc.'s (NYSE:EHAB) Revenues Are Not Doing Enough For Some Investors
Apr 09Enhabit: Healthcare Predictive Analytics, FCF, Very Undervalued
Feb 03Is Enhabit (NYSE:EHAB) A Risky Investment?
Dec 14Returns On Capital At Enhabit (NYSE:EHAB) Paint A Concerning Picture
Nov 07Is Enhabit (NYSE:EHAB) Using Too Much Debt?
Jul 17Is Enhabit Dead? Not Quite Yet
Jul 15Enhabit (NYSE:EHAB) Could Be At Risk Of Shrinking As A Company
Jun 19An Intrinsic Calculation For Enhabit, Inc. (NYSE:EHAB) Suggests It's 42% Undervalued
May 10Here's What Analysts Are Forecasting For Enhabit, Inc. (NYSE:EHAB) After Its Annual Results
Mar 09The Market Doesn't Like What It Sees From Enhabit, Inc.'s (NYSE:EHAB) Revenues Yet
Mar 05Enhabit (NYSE:EHAB) Could Be Struggling To Allocate Capital
Feb 09A Look At The Intrinsic Value Of Enhabit, Inc. (NYSE:EHAB)
Oct 04Enhabit: 40% Slump In Pre-Tax Earnings, Payer Headwinds Remain In Situ, Reiterate Hold
Aug 18Enhabit: Difficult To Justify At 20x Earnings, Reiterate Hold
Jun 07An Intrinsic Calculation For Enhabit, Inc. (NYSE:EHAB) Suggests It's 24% Undervalued
May 31Shareholder Returns
| EHAB | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0.07% | 2.6% | 0.9% |
| 1Y | 72.5% | -3.6% | 28.2% |
Return vs Industry: EHAB exceeded the US Healthcare industry which returned -3.6% over the past year.
Return vs Market: EHAB exceeded the US Market which returned 28.2% over the past year.
Price Volatility
| EHAB volatility | |
|---|---|
| EHAB Average Weekly Movement | 6.7% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: EHAB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EHAB's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 10,800 | Barb Jacobsmeyer | www.ehab.com |
Enhabit, Inc. provides home health and hospice services in the United States. The Home Health segment offers nursing care; physical, occupational, and speech therapy; medical and social work; and home health aide services. This segment also provides patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer’s disease, low vision, spinal stenosis, Parkinson’s disease, osteoporosis, complex wound care, and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery or injury, and respiratory diseases; and counseling for patients and their families regarding financial, personal, and social concerns that arise from a patient’s health-related problems.
Enhabit, Inc. Fundamentals Summary
| EHAB fundamental statistics | |
|---|---|
| Market cap | US$697.44m |
| Earnings (TTM) | -US$4.60m |
| Revenue (TTM) | US$1.06b |
Is EHAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EHAB income statement (TTM) | |
|---|---|
| Revenue | US$1.06b |
| Cost of Revenue | US$540.20m |
| Gross Profit | US$519.80m |
| Other Expenses | US$524.40m |
| Earnings | -US$4.60m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.091 |
| Gross Margin | 49.04% |
| Net Profit Margin | -0.43% |
| Debt/Equity Ratio | 78.7% |
How did EHAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 09:35 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enhabit, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joanna Sylvia Gajuk | BofA Global Research |
| Jason Cassorla | Citigroup Inc |
| Jamie Perse | Goldman Sachs |